EP
IKT icon

Essential Partners’s Inhibikase Therapeutics IKT Stock Holding History

Essential Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31K Sell
646
-1,956
-75% -$3.5K ﹤0.01% 2127
2026
Q1 		$4.37K Buy
+2,602
New +$4.62K ﹤0.01% 1643

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's IKT Position: Q2 2026 in Review

Essential Partners reduced its Inhibikase Therapeutics (IKT) stake by 75% in Q2 2026, selling an estimated $3.5K and leaving 646 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2127.

Essential Partners first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.37K in Q1 2026. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Essential Partners held 646 shares of Inhibikase Therapeutics worth $1.31K as of Q2 2026.
  • Essential Partners sold 1,956 Inhibikase Therapeutics shares in Q2 2026, an estimated $3.5K.
  • Inhibikase Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2127 holding.
  • Essential Partners first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Essential Partners's Inhibikase Therapeutics position peaked at $4.37K in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.